Day One Biopharmaceuticals gains amid takeover speculation
2026-03-04 13:04:44 ET
More on Day One Biopharmaceuticals
- Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead
- Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript
- Day One Biopharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Day One Biopharmaceuticals reiterates $225M–$250M OJEMDA revenue target as pipeline expands with Emi-Le integration
- Day One Biopharmaceuticals reports Q4 results
Read the full article on Seeking Alpha
For further details see:
Day One Biopharmaceuticals gains amid takeover speculationNASDAQ: JAZZ
JAZZ Trading
2.12% G/L:
$183.77 Last:
228,273 Volume:
$179.88 Open:



